Exchange Traded Concepts LLC Has $110,000 Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Exchange Traded Concepts LLC raised its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 42.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,861 shares of the company’s stock after purchasing an additional 3,550 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Tyra Biosciences were worth $110,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. RA Capital Management L.P. raised its stake in shares of Tyra Biosciences by 2.1% in the fourth quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company’s stock valued at $147,858,000 after acquiring an additional 220,681 shares during the last quarter. Alta Partners Management Company L.P. bought a new position in shares of Tyra Biosciences in the fourth quarter valued at approximately $56,716,000. Boxer Capital Management LLC bought a new position in shares of Tyra Biosciences in the fourth quarter valued at approximately $28,185,000. Janus Henderson Group PLC raised its stake in shares of Tyra Biosciences by 63.6% in the fourth quarter. Janus Henderson Group PLC now owns 1,746,320 shares of the company’s stock valued at $24,291,000 after acquiring an additional 679,124 shares during the last quarter. Finally, Orbimed Advisors LLC raised its stake in shares of Tyra Biosciences by 91.3% in the fourth quarter. Orbimed Advisors LLC now owns 1,470,086 shares of the company’s stock valued at $20,434,000 after acquiring an additional 701,448 shares during the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on TYRA. Piper Sandler began coverage on shares of Tyra Biosciences in a research note on Wednesday, May 21st. They issued an “overweight” rating and a $33.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Tyra Biosciences in a research note on Monday, March 31st. Finally, Wedbush reiterated an “outperform” rating and issued a $30.00 target price on shares of Tyra Biosciences in a research note on Friday, March 28th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $30.83.

Tyra Biosciences Price Performance

TYRA stock opened at $9.74 on Wednesday. The company has a 50 day moving average price of $9.81 and a 200 day moving average price of $11.66. Tyra Biosciences, Inc. has a fifty-two week low of $6.42 and a fifty-two week high of $29.60. The stock has a market capitalization of $517.10 million, a PE ratio of -5.98 and a beta of 1.07.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. As a group, equities analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Tyra Biosciences

In related news, Director Gilla Kaplan sold 30,000 shares of the company’s stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $10.31, for a total value of $309,300.00. Following the completion of the transaction, the director now directly owns 59,623 shares of the company’s stock, valued at approximately $614,713.13. This represents a 33.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders sold 61,392 shares of company stock worth $628,358. Insiders own 15.20% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.